Novocure

Historical price data

Founded in 2000 by Professor Yoram Palti, Novocure has developed a unique, physics-based cancer treatment platform that targets solid tumors with electric fields, offering a treatment option with a distinct side-effect profile. Its first commercial success came with FDA approvals for glioblastoma in 2011 and 2015, and it recently secured a landmark approval for pancreatic cancer in 2024. The company's strategy centers on broadening the clinical validation of TTFields across multiple cancer types through a robust late-stage clinical pipeline.

Tumor Treating Fields (TTFields): A non-invasive, anti-mitotic cancer therapy that uses low-intensity, alternating electric fields tuned to specific frequencies to disrupt cell division in solid tumors.

33 drugs in pipeline, 5 in Phase 3

Total raised: $205M

Novocure's TTFields therapy has no direct modality competitor, competing instead with standard drug, radiation, and surgical approaches in each cancer type. Its primary differentiation is its non-invasive mechanism and favorable safety profile, allowing for combination therapy. Major competitors include large pharma companies developing oncology drugs (e.g., Merck, Roche, AstraZeneca) and other device or radiotherapy firms.